Viewing Study NCT00333229



Ignite Creation Date: 2024-05-05 @ 4:53 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00333229
Status: TERMINATED
Last Update Posted: 2014-11-25
First Post: 2006-05-31

Brief Title: A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Study Overview

Official Title: Influence of Zoledronic Acid on Bone Mineral Density and Bone Ultrasonometry in Premenopausal Women With Hormone Receptor Negative Breast Cancer and Adjuvant Chemotherapeutic Treatment
Status: TERMINATED
Status Verified Date: 2014-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Due to rare patient population planned number of patients could not be recruited in a reasonable timeframe Recruitment was stopped prematurely
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Breast cancer and osteoporosis are two of the most frequent diseases in women Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and on bone turnover

This study is will assess the safety and efficacy of Zoledronic acid 4 mg given every 3 months over 24 months in improving bone mineral density in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment compared to placebo

This study is not recruiting patients in the United States
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2004-002831-14 None None None